Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Fulcrum Therapeutics Inc (NASDAQ: FULC) closed at $7.63 in the last session, down -0.26% from day before closing price of $7.65. In other words, the price has decreased by -$0.26 from its previous closing price. On the day, 0.53 million shares were traded. FULC stock price reached its highest trading level at $7.71 during the session, while it also had its lowest trading level at $7.28.
Ratios:
We take a closer look at FULC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 17.70 and its Current Ratio is at 17.70. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on July 29, 2025, Upgraded its rating to Buy and sets its target price to $12 from $4 previously.
On May 23, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $12.
Cantor Fitzgerald Upgraded its Neutral to Overweight on May 15, 2025, while the target price for the stock was maintained at $10.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 08 ’25 when Tourangeau Greg sold 498 shares for $5.06 per share. The transaction valued at 2,520 led to the insider holds 14,062 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FULC now has a Market Capitalization of 412923712 and an Enterprise Value of 219289680.
Stock Price History:
The Beta on a monthly basis for FULC is 3.21, which has changed by 1.0961537 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, FULC has reached a high of $10.11, while it has fallen to a 52-week low of $2.32. The 50-Day Moving Average of the stock is -8.68%, while the 200-Day Moving Average is calculated to be 26.39%.
Shares Statistics:
According to the various share statistics, FULC traded on average about 522.41K shares per day over the past 3-months and 902330 shares per day over the past 10 days. A total of 54.11M shares are outstanding, with a floating share count of 47.97M. Insiders hold about 11.36% of the company’s shares, while institutions hold 91.29% stake in the company. Shares short for FULC as of 1760486400 were 3550355 with a Short Ratio of 6.80, compared to 1757894400 on 3687485. Therefore, it implies a Short% of Shares Outstanding of 3550355 and a Short% of Float of 9.4799995.
Earnings Estimates
Fulcrum Therapeutics Inc (FULC) is presently subject to a detailed evaluation by 8.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.22 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$1.14 and -$1.21 for the fiscal current year, implying an average EPS of -$1.18. EPS for the following year is -$1.2, with 8.0 analysts recommending between -$0.86 and -$1.43.
